13 October 2020 - Confirmation underscores Moderna’s commitment to make its vaccine available in Canada.
Moderna today announced the initiation of a rolling submission to Health Canada for mRNA-1273, the Company’s vaccine candidate against COVID-19.
This initiation follows positive results from a pre-clinical viral challenge study of mRNA-1273 and the positive interim analysis of the Phase 1 study of mRNA-1273 in healthy adults (ages 18-55 years) and older adults (ages 56-70 and 71+) published in the New England Journal of Medicine.